RAPALA VMC CORPORATION, Company release, May 13, 2026 at 2:15 p.m. EEST January-March (Q1) in briefNet sales were 69.5 MEUR, up 6% from previous year (65.3).With comparable exchange rates sales were 13% up from previous year. Comparable operating profit* was 7.8 MEUR (5.6). Cash flow from operations was -3.8 MEUR (-9.3). Inventories were 82.5 MEUR (84.9). Short-term outlook: The Group expects 2026 full year comparable operating profit* to increase from 2025.President and CEO Cyrille Viellard: “A positive start to 2026 with 13% sales growth at comparable exchange rates, supported by exciting new product introductions and efficient supply chain execution, enabled an encouraging performance despite continued global market uncertainty. I would like to extend a sincere thank you to the entire Rapala VMC team for their dedication to deliver...

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended April 4, 2026. Highlights1Q 2026 revenues of $839.2 million Gross margin was 21.0% 1Q 2026 GAAP EPS of $0.05 1Q 2026 book-to-bill of 1.34 with book-to-bill of 1.47 for semiconductors and 1.23 for passive components Backlog at quarter end was 5.7 months“Vishay’s first quarter financial results demonstrate that the Vishay 3.0 strategy is working. As a result of the investments we made to expand capacity of high-growth, high-margin products, Vishay is reliably scaling with our customers. Our top priority going forward is to increase backlog turns to ensure we maintain competitive...

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoption Express Scripts national formulary coverage secured as company makes progress toward broad patient access Atrial Fibrillation-RVR Phase 3 registration trial initiated: patient enrollment to begin in H2 2026 Strong balance sheet of $184.2M provides runway into H2 2027 to fund commercial and operational priorities Company to host investor call and webcast at 8:30am ET todayMONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided...

Revenues Grew 20%, GAAP Operating Income Increased to $4.4 Million, Adjusted EBITDA Doubled to $15.1 MillionReiterates Guidance for 2026 PETAH TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the first quarter, ended March 31, 2026. First Quarter 2026 Financial HighlightsRevenues of $110.5 million, compared with $92 million in Q1 2025; GAAP operating income of $4.4 million, compared with GAAP operating loss of $2.7 million in Q1 2025; Non-GAAP operating income of $12.5 million, compared with $5.2 million in Q1 2025; GAAP net income of $5.2 million, or $0.07 per diluted share, compared with GAAP net loss of $6 million, or $0.11 loss per diluted share, in Q1 2025; Non-GAAP...

–Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027— –Company to host conference call and webcast today at 8:00 a.m. ET— MIAMI, FL, May 13, 2026 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 second quarter ended March 31, 2026, and provided a corporate update. “We are extremely pleased with the progress of the enrollment of the Phase 2b PLATEAU clinical trial to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in older patients...

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051 Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051 trial of WEE1 inhibitor APR-1051 Additional clinical data from ACESOT-1051 to be provided at the ASCO 2026 Annual Meeting on May 30, 2026 $46.5 million in cash and cash equivalents as of March 31, 2026, with anticipated cash runway into Q1 2028DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026,...

Announced with Cerberus the formation of Frontier Power USA, a stand-alone purpose-built entity to develop, finance, and operate LDES projects to accelerate energy storage deployments  Entered into a 2 GWh firm capacity reservation agreement with Frontier Power USA $57.0 million in quarterly revenue with the last two quarters surpassing full year 2025 revenue Achieved record quarterly production performance for shipments, battery output, and bipolar manufacturing Completed Factory Acceptance Testing for its second battery line with installation and power-on at the Thorn Hill facility underway; initial production is on schedule and expected to begin by the end of the second quarter Surpassed 6.0 GWh of discharged energy from Eos technology; DawnOS™ demonstrating consistent operating performance and improved round trip efficiency Expanded...